The ASGR1 Knockout LoVo Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human LoVo colorectal adenocarcinoma cell line, engineered to disrupt the ASGR1 gene and generate a loss-of-function model. ASGR1 encodes the major subunit of the asialoglycoprotein receptor, a lectin that mediates clathrin-dependent endocytosis of desialylated glycoproteins. This polyclonal knockout population enables functional studies of ASGR1 in cancer biology, including glycoprotein homeostasis and intracellular trafficking.
LoVo cells, derived from a metastatic colorectal adenocarcinoma in a 56-year-old male, are a well-established model for colon cancer, commonly used to study invasion, metastasis, and drug responses due to their genetic stability and relevance to pathways such as Wnt and EGFR. They provide a robust platform for gene editing and phenotypic analysis.
ASGR1 binds glycoproteins with terminal galactose or N-acetylgalactosamine, mediating their internalization via clathrin-coated pits. It forms a heteromeric complex with ASGR2 and interacts with adaptor AP2M1 and clathrin, with dynamin (DNM2) facilitating vesicle scission. Internalized cargo traffics through early endosomes (EEA1, RAB5) to lysosomes (RAB7, LAMP1) for degradation by cathepsins like CTSB. ASGR1 transcription is controlled by HNF4A, HNF1A, C/EBP??, and STAT3. Downstream, ASGR1-mediated clearance impacts NF-??B signaling and c-Myc expression, linking glycoprotein metabolism to cellular growth and survival.
In LoVo colorectal cancer cells, ASGR1 knockout abrogates asialoglycoprotein endocytosis, providing a system to study how glycoprotein clearance affects cancer phenotypes. Loss of ASGR1 may alter extracellular glycoprotein levels, potentially modulating receptor signaling and tumor microenvironment interactions. Given aberrant glycosylation in colorectal cancer, this model helps elucidate glycosylation-dependent effects on proliferation, migration, and drug resistance. The interplay with NF-??B and c-Myc signaling offers insights into metabolic?Concogenic crosstalk.
These knockout cells support a variety of assays: Western blot and RT-qPCR for gene disruption confirmation; asialofetuin uptake measured by flow cytometry to assess endocytic function; and cell viability, colony formation, and migration assays to evaluate cancer cell phenotypes. Co-immunoprecipitation and lysotracker staining enable interaction and lysosomal studies. The model is also useful for drug delivery research targeting ASGR1 and exploring off-target effects in colorectal cancer. It facilitates investigation of glycoprotein-dependent metabolic reprogramming and signal transduction. For further information, please contact Ascent Research.
